Caricamento quotazioni...
Previsioni
Il prezzo obiettivo medio degli analisti è 1310,66 € (-0,20%). La mediana è 1308,44 € (-0,37%).
| Acquista |
Â
34 |
| Mantieni |
Â
9 |
| Vendi |
Â
3 |
Discussioni nella community
Tradotto (originale in tedesco)
Vendere o mantenere NovoCiao a tutti, sto ancora riflettendo se dovrei vendere la mia posizione in Novo e trasferire i fondi nei miei ETF (All World/High Dividendi). Ho acquistato questo titolo qualche tempo fa, all'epoca…
D Denny II in Portfolio Roasts
6 35
Notizie Vai al feed delle notizie
Eli Lilly gets approval in China for oral GLP-1 therapy orforglipron
Eli Lilly has received China's first approval for an oral GLP-1 active ingredient for weight loss, orforglipron, securing a strategic lead in the world's second-largest pharmaceutical market. The tablet form substantially expands the addressable patient pool versus injectable preparations and is likely to add revenue to the obesity business. Analysts see billion-dollar market potential in China, while Lilly’s pipeline, including retatrutide and other candidates, offers additional growth sources. The combination of market access, a strong obesity business and a broad pipeline supports the stock's current upward trend. » Altro su deraktionaer.de
Eli Lilly's Foundayo cuts severity of obstructive sleep apnea in late-stage trial, company to seek FDA approval
Foundayo significantly reduced apnea-hypopnea index (AHI) and hypoxic burden versus placebo in two late-stage studies of adults with obesity or overweight, with non-PAP patients seeing an average reduction of 21.1 AHI events per hour versus 4.8 for placebo and a 43.8% overall AHI decrease. Lilly plans to file for U.S. approval by year-end for a daily pill to treat moderate-to-severe obstructive sleep apnea. The drug also produced roughly 11% average weight loss at 52 weeks and lowered an inflammation marker; common side effects were gastrointestinal and led to higher discontinuation rates versus placebo. » Altro su cnbc.com
Eli Lilly raises outlook — pipeline candidates could deliver next growth wave
Eli Lilly surprised with strong quarterly results and raised its full-year guidance. Growth is currently being driven by Mounjaro and Zepbound, while Retatrutide, Foundayo and EloraTZP are advancing in clinical trials and could provide substantial additional revenue if approved. The company is also expanding production capacity in Texas and Virginia to meet demand. The pipeline’s progress and recently released data support the outlook for continued growth. » Altro su deraktionaer.de
Eli Lilly in focus: quarterly report decides valuation premium for healthcare stocks
Healthcare stocks have strongly recovered since April and are now trading at higher valuations than the broader market, after the sector traded at about a 25% discount a year ago. The rotation is seen mainly as a contrarian bet against the AI boom, with investors pulling money from tech ETFs into pharma and medical names; Johnson & Johnson and Eli Lilly account for a large share of the premium. Whether the higher valuation holds depends, analysts say, on whether medical innovation builds confidence, political risks remain muted, and large companies like Eli Lilly meet high expectations in their quarterly results. Today's quarterly report and Eli Lilly's conference call are seen as a key test of the sustainability of the healthcare rally. » Altro su finanzen.net
Eli Lilly raises price target after beat-and-raise quarter powered by GLP-1 drugs
Eli Lilly reported third-quarter revenue of $24.4 billion (+39% y/y) and adjusted EPS of $7.48, both above consensus, driven by strong Mounjaro and Zepbound sales. Management raised full-year revenue guidance to $91–$92 billion and the outlet raised its price target to $1,500, citing sustained volume growth that offsets lower realized prices. Foundayo pill sales lagged estimates, but executives highlighted large market expansion potential and progress on next-generation obesity and diabetes candidates. » Altro su cnbc.com
Dividendi storici Dividendi
Tutte le metriche sui dividendi Tutte le metricheDati finanziari dell'azienda
| (EUR) | settembre 2026 | YoY |
|---|---|---|
| Ricavi | 21,54Â Mld | 43,61% |
| Utile lordo | 18,07Â Mld | 45,29% |
| Utile netto | 5,7Â Mld | 19,72% |
| EBITDA | 8,24Â Mld | 22,62% |
Dati fondamentali
| Metrica | Valore |
|---|---|
Capitalizzazione di mercato | 1,23 Bln € |
Numero di azioni | 940,75Â Mln |
Massimo/minimo a 52 settimane | 1326,61 € - 772,81 € |
Rendimento da dividendo | 0,44% |
Dividendi TTM | 5,76 € |
Prossimo dividendo | 1,57 € |
Beta | 0,45 |
Rapporto P/E | 46,73 |
Rapporto PEG | 0,92 |
Rapporto P/B | 31,97 |
Rapporto P/S | 15,71 |
Profilo aziendale
Eli Lilly and Company scopre, sviluppa e commercializza farmaci per uso umano in tutto il mondo. Offre Basaglar, Humalog, Humalog Mix 75/25, Humalog U-100, Humalog U-200, Humalog Mix 50/50, insulina lispro, insulina lispro protamina, insulina lispro mix 75/25, Humulin, Humulin 70/30, Humulin N, Humulin R e Humulin U-500 per il diabete; e Jardiance, Trajenta e Trulicity per il diabete di tipo 2. L'azienda fornisce Alimta per il carcinoma polmonare non a piccole cellule (NSCLC) e il mesotelioma pleurico maligno; Cyramza per il carcinoma gastrico metastatico, l'adenocarcinoma della giunzione gastro-esofagea, il NSCLC metastatico, il carcinoma colorettale metastatico e il carcinoma epatocellulare; Erbitux per i tumori colorettali e vari tumori della testa e del collo; Retevmo per il NSCLC metastatico, il carcinoma midollare della tiroide e il carcinoma tiroideo; Tyvyt per il linfoma classico di Hodgkin recidivato o refrattario e il NSCLC non squamoso; e Verzenio per il carcinoma mammario metastatico HR+, HER2-, il carcinoma mammario con linfonodi positivi e il carcinoma mammario in fase precoce. Offre Olumiant per l'artrite reumatoide; e Taltz per la psoriasi a placche, l'artrite psoriasica, la spondilite anchilosante e la spondiloartrite assiale non radiografica. L'azienda offre Cymbalta per il disturbo depressivo, il dolore neuropatico periferico diabetico, il disturbo d'ansia generalizzato, la fibromialgia e il dolore muscoloscheletrico cronico; Emgality per la prevenzione dell'emicrania e la cefalea a grappolo episodica; e Zyprexa per la schizofrenia, il disturbo bipolare di tipo I e il trattamento di mantenimento del disturbo bipolare. I suoi anticorpi Bamlanivimab ed Etesevimab, e Bebtelovimab per il COVID-19; Cialis per la disfunzione erettile e l'iperplasia prostatica benigna; e Forteo per l'osteoporosi. L'azienda collabora con Incyte Corporation; Boehringer Ingelheim Pharmaceuticals, Inc.; AbCellera Biologics Inc.; Junshi Biosciences; Regor Therapeutics Group; Lycia Therapeutics, Inc.; Kumquat Biosciences Inc.; Entos Pharmaceuticals Inc.; e Foghorn Therapeutics Inc. Eli Lilly and Company è stata fondata nel 1876 e ha sede a Indianapolis, Indiana.
| Nome | Eli Lilly & Co |
| CEO | David A. Ricks |
| Sede centrale | Indianapolis,
in Stati Uniti |
| Sito web | |
| Settore | SanitĂ |
| Industria | Prodotti farmaceutici |
| Quotazione in borsa | 01/06/1972 |
| Dipendenti | 50.000 |
Simboli di borsa
| Borsa | Simbolo |
|---|---|
NYSE | LLY |
XETRA | LLY.DE |
SIX | LLY.SW |
Frankfurt | LLY.F |
DĂĽsseldorf | LLY.DU |
Hamburg | LLY.HM |
Milan | 1LLY.MI |
London | 0Q1G.L |
MĂĽnchen | LLY.MU |
Wien | LLYC.VI |